Mesenchymal Stem Cells and Cardiomyocytes Interplay to Prevent Myocardial Hypertrophy

This study found that mesenchymal stem cells may crosstalk with cardiomyocytes, which causes a synergistic vascular endothelial growth factor (VEGF) release from both kinds of cells and then inhibits pathological cardiac remodeling following hypertrophic stimulation in cardiomyocytes in vitro and in vivo. Blockage of VEGF release from bone marrow-derived mesenchymal stem cells (BMSCs) abolishes the antihypertrophic actions of BMSCs in vitro and in vivo. On the contrary, VEGF administration attenuates hypertrophic signaling of calcineurin/ nuclear factor of activated T cell cytoplasmic 3 signal pathways. This study provides the first evidence for the treatment of myocardial hypertrophy using BMSCs.

Source: Stem Cells Translational Medicine - December 10, 2015 Category: Stem Cells Authors: Cai, B., Tan, X., Zhang, Y., Li, X., Wang, X., Zhu, J., Wang, Y., Yang, F., Wang, B., Liu, Y., Xu, C., Pan, Z., Wang, N., Yang, B., Lu, Y. Tags: Tissue-Specific Progenitor and Stem Cells, Mesenchymal Stem Cells Source Type: research